SPY342.73-0.65 -0.19%
DIA281.97-0.98 -0.35%
IXIC11,484.69-31.80 -0.28%

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting

New data demonstrate a sustained patient benefit following SER-109 administration with a highly statistically significant 31.1% absolute reduction in the rate of C. difficile infection recurrence over 12 weeks,

· 10/12/2020 07:09
  • New data demonstrate a sustained patient benefit following SER-109 administration with a highly statistically significant 31.1% absolute reduction in the rate of C. difficile infection recurrence over 12 weeks, compared to placebo –
  • Additional new findings show similar SER-109 efficacy across stratified age groups and prior antibiotic treatment regimen cohorts –
  • Well tolerated, with a safety profile comparable to placebo –
  • SER-109 open label study enrolling individuals with recurrent C. difficile infection –